For patients being converted from intravenous to oral MMF early post-transplant, the potential increased risk for development of aGVHD due to lower bioavailability should be considered.
limitations to our study include use of data from three previously published studies [4 , 30 , 31], and therefore the pharmacogenetic analysis was retrospective in design.